A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Former U.S. Assistant Secretary of Defense Andrew Weber Appointed to Zeteo Tech BOD

What To Know

  • He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.
  • Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds.

Former U.S. Assistant Secretary of Defense Andrew Weber has been appointed to Zeteo Tech board of directors. The news was announced today. Mr. Weber served as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama.

“Andy has dedicated much of his professional career working to strengthen our Nation’s security and response to nuclear, chemical, and biological threats,” said Wayne Bryden, PhD, President and CEO of Zeteo Tech. “We are delighted that he is joining the Board, and his unmatched wealth of knowledge and experience will be greatly utilized as Zeteo continues to grow its commercial and government offerings.”

Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds. A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

In addition to Mr. Weber’s public service as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, he was a driving force behind Nunn-Lugar Cooperative Threat Reduction efforts to remove weapons-grade uranium from Kazakhstan and Georgia and nuclear-capable MiG-29 aircraft from Moldova, to reduce biological weapons threats, and to destroy Libyan and Syrian chemical weapons stockpiles. Mr. Weber also coordinated leadership of the international Ebola response for the U.S. Department of State.

Prior to joining the Pentagon as Advisor for Threat Reduction Policy in December 1996, Mr. Weber was posted abroad as a U.S. Foreign Service Officer in Saudi ArabiaGermanyKazakhstan, and Hong Kong. Mr. Weber is an independent consultant and a Strategic Advisor for Ginkgo BioWorks. He serves on the Boards of Healthcare Ready and the Arms Control Association, and the James Martin Center for Non-proliferation Studies International Advisory Council.

Mr. Weber taught at the Georgetown University Graduate School of Foreign Service for seven years and was a Senior Fellow at the Harvard Kennedy School’s Belfer Center for Science and International Affairs. Mr. Weber graduated from Cornell University and holds a Master of Science in Foreign Service (MSFS) degree from Georgetown University. He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.

 

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

“Adding Michael to the Avation leadership team is our next step in launching Vivally,” said Jill Schiaparelli, founder and CEO of Avation Medical. “Patients have been crystal clear that they want a surgical-free, non-invasive treatment option for their OAB symptoms. Our focus now is to ensure that Vivally is easily accessible to the 46 million patients suffering from OAB in this country.”
Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno Biosciences since 2017.
Peter Eckes offers more than a 30-year career in the agricultural industry, and provides a unique appreciation for what it takes to bring innovation to the modern agriculture marketplace at scale without losing sight of farmer and consumer needs.

By using this website you agree to accept Medical Device News Magazine Privacy Policy